New hope for High-Risk blood cancer: targeted therapy shows promise

NCT ID NCT03383575

First seen Feb 28, 2026 · Last updated May 14, 2026 · Updated 15 times

Summary

This study tests a combination of two drugs, enasidenib and azacitidine, in people with a rare, high-risk blood cancer called IDH2-mutant myelodysplastic syndrome. The goal is to see if the treatment can control the disease and reduce side effects. About 63 participants will take part in this phase 2 trial at M.D. Anderson Cancer Center.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDH2 GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cleveland Clinic Foundation

    ACTIVE_NOT_RECRUITING

    Cleveland, Ohio, 44195, United States

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    ACTIVE_NOT_RECRUITING

    Baltimore, Maryland, 21287, United States

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-••••

    Contact

Conditions

Explore the condition pages connected to this study.